|
|
Blood, 15 November 2007, Vol. 110, No. 10, pp. 3673-3681.
Prepublished online as a Blood First Edition Paper on August 9, 2007; DOI 10.1182/blood-2007-04-087171.
Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis
Philip O. Scumpia1,
Matthew J. Delano1,
Kindra M. Kelly-Scumpia2,
Jason S. Weinstein2,
James L. Wynn1,
Robert D. Winfield1,
Changqing Xia3,
Chun Shiang Chung4,
Alfred Ayala4,
Mark A. Atkinson3,
Westley H. Reeves2,
Michael J. Clare-Salzler3, and
Lyle L. Moldawer1
Departments of 1 Surgery,
2 Medicine, and
3 Pathology, University of Florida College of Medicine, Gainesville; and
4 Division of Surgical Research/Department of Surgery, Rhode Island Hospital and Brown University School of Medicine, Providence
Apoptosis of CD4+ T cells and TH2 polarization are hallmarks of sepsis-induced immunoparalysis. In this study, we characterized sepsis-induced adaptive immune dysfunction and examined whether improving T-cell effector function can improve outcome to sepsis. We found that septic mice produced less antigen-specific T-cell–dependent IgM and IgG2a antibodies than sham-treated mice. As early as 24 hours after sepsis, CD4+ T cells proliferated poorly to T-cell receptor stimulation, despite normal responses to phorbol myristate acetate and ionomycin, and possessed decreased levels of CD3 . Five days following immunization, CD4+ T cells from septic mice displayed decreased antigen-specific proliferation and production of IL-2 and IFN- but showed no difference in IL-4, IL-5, or IL-10 production. Treatment of mice with anti-GITR agonistic antibody restored CD4+ T-cell proliferation, increased TH1 and TH2 cytokine production, partially prevented CD3 down-regulation, decreased bacteremia, and increased sepsis survival. Depletion of CD4+ T cells but not CD25+ regulatory T cells eliminated the survival benefit of anti-GITR treatment. These results indicate that CD4+ T-cell dysfunction is a key component of sepsis and that improving T-cell effector function may be protective against sepsis-associated immunoparalysis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
K. M. Kelly-Scumpia, P. O. Scumpia, M. J. Delano, J. S. Weinstein, A. G. Cuenca, J. L. Wynn, and L. L. Moldawer
Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10
J. Exp. Med.,
January 18, 2010;
(2010)
jem.20091959v2.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. L. Wynn, P. O. Scumpia, R. D. Winfield, M. J. Delano, K. Kelly-Scumpia, T. Barker, R. Ungaro, O. Levy, and L. L. Moldawer
Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists
Blood,
September 1, 2008;
112(5):
1750 - 1758.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|